Alzheimer’s drug lecanemab, EMA re-examining marketing authorisation [Advocacy Lab Content]

The European Medicines Agency’s human medicines committee is re-examining the marketing authorisation application for the Alzheimer’s disease (AD) drug lecanemab, a treatment that has been shown to slow cognitive decline.